Stock Information
IDEAYA Biosciences Inc (IDYA)
Ticker Symbol: IDYA
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $2,870.20 mil
Piotroski score: 2
PE Ratio: N/A
EPS (TTM): -1.3024
Revenue (TTM): $2.47 M
Dividend Yield: N/A%
ROE: -11.05%
Latest News
-
Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $35
Tue, Apr 14, 2026 11:57 AM
-
Wells Fargo Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $48
Tue, Apr 14, 2026 10:51 AM
-
RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $53
Tue, Apr 14, 2026 10:18 AM
-
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $58
Tue, Apr 14, 2026 9:46 AM
-
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $54
Tue, Apr 14, 2026 9:09 AM
-
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma - Slideshow
Mon, Apr 13, 2026 4:33 PM
-
Ideaya Biosciences: Stock Buoyant On Good MUM Data - But Approval Not A Formality
Mon, Apr 13, 2026 3:29 PM
-
Ideaya Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial of Darovasertib in Combination with Crizotinib in First-Line Hla-A*02: 01-Negative Metastatic Uveal Melanoma
Mon, Apr 13, 2026 12:51 PM
-
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript
Mon, Apr 13, 2026 12:11 PM
-
Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday
Mon, Apr 13, 2026 10:29 AM
Key Financials
Financial data not available
